mCRPC patients receiving 225Ac-PSMA-617 therapy in post androgen deprivation therapy setting: Response to treatment and survival analysis

225Ac-PSMA-617, targeting the prostate-specific membrane antigen (PSMA) which is overexpressed on prostate cancer cells, has shown a remarkable therapeutic efficacy in heavily pre-treated metastatic castration-resistant prostate carcinoma patients. Here we report on treatment outcome and survival using this novel treatment modality in a series of 53 metastatic castration resistant prostate carcinoma patients directly following their androgen deprivation treatment. 225Ac-PSMA-617 was administered to 53 mCRPC patients directly following their androgen deprivation therapy. 68Ga-PSMA PET/CT was obtained at baseline, before every treatment cycle and on follow-up for selection of patients for treatment, to determine the activity to be administered and for response assessment. Serial prostate specific antigen (PSA) was obtained for PSA response assessment.

SATHEKGE Mike;  BRUCHERTSEIFER Frank;  VORSTER Mariza;  LAWAL I;  KNOESEN Otto;  MAHAPANE Johncy;  DAVIS Cindy;  MDLOPHANE Amande;  MAES A;  MOKOALA K;  MATHABE Kgomotso;  VAN DE WIELE C;  MORGENSTERN Alfred; 

2022-12-16

SOC NUCLEAR MEDICINE INC

JRC128334

0161-5505 (online),   

https://publications.jrc.ec.europa.eu/repository/handle/JRC128334,   

10.2967/jnumed.121.263618 (online),